Get the Stockscreener App
188.48
2.81%
5.08
After Hours:
188.48
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $188.48, with a volume of 2.58M.
It is up +2.81% in the last 24 hours and down -9.54% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$183.40
Open:
$190.88
24h Volume:
2.58M
Relative Volume:
0.59
Market Cap:
$292.30B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
57.48
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
+2.70%
1M Performance:
-9.54%
6M Performance:
+155.64%
1Y Performance:
+158.87%
1-Day Range:
$188.40
$192.97
1-Week Range:
$182.39
$192.97
52-Week Range:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
188.48 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
877.66 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.36 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.32 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca advances Friday, outperforms market - MarketWatch
UK's FTSE 100 Ends Week Little Changed; AstraZeneca Shares Gain - marketscreener.com
AstraZeneca Expands DNA-Repair Oncology Pipeline With New AZD4956 Combination Trial - TipRanks
Astrazeneca (NYSE:AZN) Shares Gap UpHere's What Happened - MarketBeat
AstraZeneca lung drug gets ‘surprise’ win in COPD trials - biopharmadive.com
Buying pressure lifts AstraZeneca stock higher in today's trading - Traders Union
ASTRAZENECA : Receives a Buy rating from Barclays - marketscreener.com
ASTRAZENECA : Jefferies maintains a Buy rating - marketscreener.com
ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com
International ETFs: EEM and IEFA Offer Distinct Global ETF Choices - The Motley Fool
Concerning safety signals and positive efficacy for AstraZeneca’s in vivo CAR-T - Clinical Trials Arena
AstraZeneca Maintained at Buy as BofA Notes Positive Tozorakimab Late-stage Data - marketscreener.com
AstraZeneca (AZN.US) Experimental Lung Disease Drug Meets Targets in Late-Stage Trials; Stock Rises 4% Pre-Market - AASTOCKS.com
Why Is AstraZeneca Stock Gaining Friday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca’s novel COPD drug secures double win in Phase III - Clinical Trials Arena
AstraZeneca PLC Announces Tozorakimab Meets Primary Endpoints in OBERON and TITANIA Phase III Trials - marketscreener.com
AstraZeneca (AZN) reports Phase III COPD success for IL‑33 biologic tozorakimab - Stock Titan
AstraZeneca posts Phase 3 trial win for COPD drug (AZN:NYSE) - Seeking Alpha
AstraZeneca Scores First IL-33 Win In COPD With Tozarakimab - Citeline News & Insights
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD - AstraZeneca
AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials - London South East
AstraZeneca stock gains on positive COPD trial results - Investing.com
AstraZeneca's COPD candidate succeeds in twin Phase III studies - Sharecast.com
AstraZeneca PLC: Good timing to anticipate a continuation of the trend - marketscreener.com
AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials - Proactive financial news
AstraZeneca says tozorakimab meets primary endpoint in Oberon and Titania phase III COPD trials - marketscreener.com
AstraZeneca Achieves Breakthrough with Tozorakimab in COPD Trials - Devdiscourse
AstraZeneca drug reduces COPD flare ups in late-stage trials - Reuters
AstraZeneca : Tozorakimab met OBERON/TITANIA primary endpoints - marketscreener.com
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - Barchart.com
ASTRAZENECA : Receives a Sell rating from Deutsche Bank - marketscreener.com
AstraZeneca PLC ADRhedged (AZNH) Stock Price, Holdings, Dividend Yield - GuruFocus
Cash per share of AstraZeneca PLC – SWB:ZEG - TradingView
AstraZeneca plc stock faces pipeline scrutiny amid oncology setbacks and regulatory delays in key ma - ad-hoc-news.de
AstraZeneca plc stock faces pipeline scrutiny amid oncology data delays and US reimbursement shifts - AD HOC NEWS
AstraZeneca (AZN) Announces EU Approval of Imfinzi for Early Gastric/Gastroesophageal Cancers - Insider Monkey
AstraZeneca’s CHOICE Survey Targets Real-World Drivers of EGFR-TKI Use in China - TipRanks
Professional Advisory Services Inc. Has $28.12 Million Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
Cybercrime group Lapsus$ claims the hack of pharma giant AstraZeneca - Security Affairs
Assenagon Asset Management S.A. Has $72.36 Million Holdings in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca: The Big China Bet (NYSE:AZN) - Seeking Alpha
AstraZeneca reportedly hit by serious cyberattack - pharmaphorum
AstraZeneca PLC (AZN) gains after successful Saphnelo trial - MSN
Astrazeneca plc Announces In-Licensing of Worldwide Rights from Astrazeneca to A Phase 3?Ready Novel Chemical Entity - marketscreener.com
AstraZeneca Data Breach: What You Need to Know - SOCRadar® Cyber Intelligence Inc.
Westview Management dba Westview Investment Advisors Invests $3.60 Million in Astrazeneca Plc $AZN - MarketBeat
Gradient Investments LLC Has $16.96 Million Holdings in Astrazeneca Plc $AZN - MarketBeat
LAPSUS$ Hackers Claim Breach of AstraZeneca’s Internal Systems - cyberpress.org
J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a £140 PT - MSN
AstraZeneca Data BreachLAPSUS$ Group Allegedly Claims Access to Internal Data - CyberSecurityNews
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):